MaxCyte, Inc. (LON:MXCT - Get Free Report) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 180.07 ($2.45) and traded as low as GBX 152.96 ($2.08). MaxCyte shares last traded at GBX 165 ($2.25), with a volume of 18,641 shares traded.
MaxCyte Stock Up 0.6%
The stock has a market cap of £208.57 million, a P/E ratio of -5.79 and a beta of 1.13. The firm has a 50 day simple moving average of GBX 178.87 and a 200-day simple moving average of GBX 258.95. The company has a quick ratio of 14.38, a current ratio of 9.81 and a debt-to-equity ratio of 8.59.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Featured Articles
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
